Macrogenics Analyst Price Targets

Macrogenics Inc

MGNXNASDAQ

Trade with Public

$3.35

0.103.23%

最終更新: Oct 19, 1:08 PM

$3.25

N/A

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Macrogenics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Macrogenics (MGNX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

4Buy

7Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$8Upside to Avg. PT+138.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$9→$11
Apr 20, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$4→$6
Apr 10, 2026	B. Riley Securities	Mayank Mamtani	Upgrade	Neutral→Buy	$3→$9
Mar 10, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$3→$4
Nov 3, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$2
Sep 17, 2025	Barclays	Etzer Darout	Assumes	Overweight	$3
Aug 15, 2025	Leerink Partners	—	PT Cut	Outperform	$8→$5
May 20, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Neutral	$5→$3
May 14, 2025	Stifel	Stephen Willey	PT Cut	Hold	$6→$5
May 14, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$8→$3
Mar 25, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Neutral	$4→$2
Nov 7, 2024	JMP Securities	Silvan Tuerkcan	Downgrade	Market Outperform→Market Perform	—
Nov 6, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Sep 18, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Aug 21, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4
Aug 15, 2024	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$16→$14
Aug 7, 2024	Stifel	Stephen Willey	PT Cut	Hold	$7→$6
Aug 7, 2024	BMO Capital	Etzer Darout	PT Cut	Market Perform	$8→$5
Aug 1, 2024	BTIG	Kaveri Pohlman	Downgrade	Buy→Neutral	—
Aug 1, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $3 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $2 price target.

Benzinga Newsdesk

4 Analysts Assess Macrogenics: What You Need To Know

Benzinga Insights

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $5 to $3.

Benzinga Newsdesk

Macrogenics Inc

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

ニュース

パートナーシップ

ベンジンガ・グローバル

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

People Also Watch

People Also Watch

Macrogenics Inc

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PROHC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PROB. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

ニュース

パートナーシップ

ベンジンガ・グローバル

Macrogenics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PROBarclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PROHC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

4 Analysts Assess Macrogenics: What You Need To Know

PROB. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

People Also Watch

People Also Watch

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3

PRO
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6

PRO
Barclays Maintains Overweight on Macrogenics, Raises Price Target to $4

PRO
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $2 Price Target

PRO
B. Riley Securities Maintains Neutral on Macrogenics, Lowers Price Target to $3